Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers
暂无分享,去创建一个
C. Vnencak-Jones | A. Kassim | J. Greer | B. Savani | M. Jagasia | S. Strickland | S. Goodman | B. Engelhardt | S. Sengsayadeth | S. Goodman | C. Lucid